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Abstract
Background: Preoperative hypercapnia and hypoxemia are reportedly risk factors for postoperative complications.
This study aimed to establish the long-term survival risk associated with abnormal preoperative arterial blood gases
(ABGs) in patients with non-small cell lung cancer (NSCLC).
Methods: This study involved 414 patients with stage I NSCLC who underwent lobectomy/bilobectomy with
mediastinal lymph node dissection. The patients were divided into groups with normal (n = 269) and abnormal
(n = 145) ABGs.
Results: The patients in the normal ABG group (median age 67 years) were significantly younger than those in
the abnormal ABG group (median age 70 years). There were no significant differences between the groups in
gender, performance status, pathological stage, histology, postoperative complications, or preoperative comorbidity,
except for chronic obstructive pulmonary disease/pulmonary fibrosis. The 3-, 5- and 10-year survival rates in the normal
and abnormal ABG groups were 87, 77 and 56, and 78 , 63 and 42 %, respectively (p = 0.006). According to multivariate
analysis, age, gender, performance status, non-adenocarcinoma, differentiation of resected tumor, pathological stage,
any prior tumor and abnormal ABGs (risk ratio, 1.61) were independent prognostic factors.
Conclusions: Abnormal ABGs predict long-term survival risk in patients with NSCLC, which is important for planning
therapeutic strategies.
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Background
Surgery is the most effective therapy for early non-small cell
lung cancer (NSCLC). Indeed, the 5-year survival rates in
patients who underwent pulmonary resection were as fol-
lows: clinical stage IA, 82.0 % (n = 6295); pathological stage
IA 86.8 % (n = 4978); clinical stage IB, 66.8 % (n = 2339);
and pathological stage IB 73.9 % (n = 2552) [1]. The 5-
and 10-year survival rates of 799 patients with
screening-detected clinical stage I lung cancer who did
not undergo surgical treatment were only 16.6 and
7.4 %, respectively [2]. A recent study of Japanese pa-
tients with operable cancer who elected to undergo
stereotactic ablative radiotherapy reported 5-year over-
all survival rates of 72 and 62 % for stage IA and IB
subgroups, respectively [3]. Therefore, anatomical lob-
ectomy is performed in most cases, which is acceptable
from a physiological point of view.
Prior to surgical treatment, oncological and physio-
logical tolerance of the proposed procedure should be
considered. To assess physiological tolerance, cardiopul-
monary function evaluation, including general respiratory
function tests, arterial blood gas (ABG) analysis, electro-
cardiography, and echocardiography, is important accord-
ing to two recent sets of guidelines [4, 5]. According to a
review of preoperative evaluation of lung cancer resection
candidates, active smoking, dyspnea, age, proposed extent
of surgery, and presence of vascular disease, diabetes
mellitus and dysrhythmia are variably associated with
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increased risks of complications and/or mortality [6]. One
study reported that 37 % of individuals who present with
anatomically resectable disease are deemed unsuitable for
surgery on the basis of poor pulmonary function alone [7].
Moreover, physiological variables have recently been
shown to influence not only perioperative outcomes,
but also long-term quality of life and survival after pul-
monary resection in patients with NSCLC. Quality of
life, particularly as it is related to physical function,
such as forced expiratory volume in 1 s (FEV1.0) and
diffusion capacity of the lungs for CO (DLCO) [8–10], is
affected after surgical resection.
ABG tests have also been used to evaluate pulmonary
function before thoracic surgery to prevent subsequent re-
spiratory insufficiency. Historically, hypercapnia (partial
pressure of CO2 in arterial blood [PaCO2] >45 Torr) has
been considered an exclusion criterion for pulmonary re-
section [11, 12]. Hypercapnia and hypoxemia (<60 Torr
partial pressure of O2 in arterial blood [PaO2] or <90 %
oxygen saturation [SaO2]) are reportedly risk factors for
postoperative complications [5]. However, according to
British Thoracic Society guidelines, hypercapnia alone is
not a predictor of complications after lung resection. Such
patients are often precluded because of other adverse fac-
tors, such as postoperative FEV1.0 and DLCO <40 % [13].
It has not been reliably established whether preopera-
tive abnormal ABGs, such as low oxygenation, hyper-
capnia or hypocapnia, are predictors of prognosis in
patients who undergo pulmonary resection. The hy-
pothesis of this study is that abnormal ABG parameters
are independently associated with a higher risk of long-
term mortality, especially non-cancer related mortality.
Given that the outcomes are not biased by organ failure
caused by tumor compression or involvement, this study
aimed to examine the correlation between preoperative




The medical records of 587 continuous patients who
underwent pulmonary resection for pathological stage I
NSCLC at Osaka City University Hospital, from January
1998 to December 2012, were analyzed retrospectively.
The following patients were excluded from the analysis:
those who underwent partial/wedge resection, without
radical mediastinal lymph node dissection (R0) as previ-
ously described [14], and those who underwent neoadju-
vant therapy for lung cancer. Ultimately, the records of
414 patients with pathological stage I NSCLC who under-
went lobectomy/bilobectomy with R0 were examined. Sur-
gery was performed through an axillary mini-thoracotomy
(assisted by video) or posterolateral thoracotomy (when
extended lobectomy, e.g., chest wall resection, pulmonary
arterioplasty or bronchoplasty was necessary). Histological
classification was performed according to the World Health
Organization criteria for histological typing of lung tumors
[15]. Postoperative staging was based on the international
TNM classification for lung cancer [16, 17]. Patients were
followed at 1–6-month intervals postoperatively. Follow-up
evaluation included physical examination, chest X-ray, and
blood examination, including for tumor markers. Chest,
brain and abdominal computed tomography were per-
formed at 3 − 6-month intervals. Bone scanning was not
routinely performed in asymptomatic patients. Whenever
any symptoms or signs of recurrence were detected, mag-
netic resonance imaging of the brain and bone scintigraphy
was performed. The patients (n = 53 /191; 28 %) with stage
1A (T1b) and 1B adenocarcinoma received oral fluoropyri-
midine for 2 years. Dose escalation or schedule modifica-
tion occurred at the discretion of the clinician. Patients
underwent chemotherapy, radiotherapy, or the best avail-
able supportive care when recurrence was detected. The
study was performed in accordance with the Declaration of
Helsinki and received approval from the Institutional
Review Board of the Osaka City University (Osaka, Japan,
reference number 2793) with waiver of informed consent
because of its retrospective design.
Data collection and follow-up evaluation
The patients’ demographic data, surgical outcomes, and
complications were reviewed, and the survival rate was
analyzed. Follow-up results and causes of death were ob-
tained from patients’ medical records (in our institute and
with their practitioners/pulmonologists) and telephone
calls, and the last follow-up day was June 30, 2015.
In-hospital mortality included all deaths during the
first 30 days or postoperative hospital stay. Postoperative
complications were classified as major (potentially life-
threatening) or minor (not life-threatening) occurring
within 30 days after surgery or bronchopleural fistula
within 3 months. Prolonged air leakage was defined as
persisting for >5 days after surgery. Prolonged pleural
effusion was defined as >1.5 L until 5 days after surgery.
Either or both predicted postoperative FEV1.0 and DLCO
<40 % were defined as high-risk comorbidity. Pulmonary
assessment included complete history, physical examin-
ation, and pulmonary function tests (PFTs). Predicted
postoperative lung function was calculated by the seg-
ments method based on the total number of segments
(42), then corrected for segments that were obstructed
by tumor preoperatively [18]. In our physiological exclu-
sion criteria, postoperative FEV1.0 ≥ 600 mL was considered
a prerequisite for resection. However, PaCO2 ≤ 50 Torr was
considered a prerequisite for resection traditionally, but we
did not exclude patients with only hypercapnia. This study
included three patients with PaCO2 > 50 Torr (50.6, 50.3
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and 50.2 Torr, respectively) and all patients had postopera-
tive FEV1.0 ≥ 600 mL.
ABG
The patients were divided into two groups according to the
results of ABG analysis: a normal ABG group (n = 269) and
an abnormal ABG group (n = 145) from a previous re-
port [19] and our institution. The abnormal group in-
cluded at least one of the following parameters: [1]
PaO2 ≤ 80 Torr (n = 83, median 75, range 62–79; [2]
PaCO2 ≤ 35 Torr (n = 22, median 34.0, range 31.1–34.9)
or ≥45 Torr (n = 50, median 46.1, range, 45.0–50.6); or
[3] pH ≤7.35 (n = 5, median 7.335, range 7.332–7.349),
or ≥7.45 (n = 14, median 7.456, range 7.451–7.485).
Statistical analysis
Comparison of continuous and dichotomous variables
between the two groups was performed using the Mann
−Whitney U test, the χ2 test, or Fisher’s exact test. The
Kaplan −Meier method and log-rank test were used for
survival analysis. Multivariate analysis was performed
with a Cox regression model with forward stepwise se-
lection and multivariate risk ratios with 95 % confidence
intervals (CIs) were calculated. P < 0.05 was considered
statistically significant. Statistical analysis was performed
using JMP 10 software (SAS Institute, Cary, NC, USA).
Results
Clinicopathological features
Of these 414 patients, 302 had adenocarcinoma, 99
squamous cell carcinoma, eight adenosquamous carcin-
oma, and five large cell carcinoma. As to pathological
stage, 232 patients were in stage IA and 182 in stage IB.
Table 1 shows the clinicopathological characteristics of
the two groups. The patients in the normal ABG group
(median age 67 years) were significantly younger than
those in the abnormal ABG group (median age 70 years)
(p = 0.005, Mann −Whitney U test). There were no sig-
nificant differences in gender, body mass index, smoking
history, Eastern Cooperative Oncology Group perform-
ance status (PS), Hugh–Jones (H–J) classification, post-
operative predicted PFTs, histology and differentiation of
the resected tumor, pathological stage, tumor location,
surgical procedures, blood loss, operative time, and adju-
vant therapy between the two groups.
Preoperative comorbidity and postoperative
complications
The postoperative course was uneventful in 281 patients
and one hospital death was associated with acute exacer-
bation of interstitial pneumonia (IP). As shown in Table 2,
there were no significant differences in preoperative co-
morbidity, such as any prior tumor, hypertension, diabetes
mellitus, and cerebral, cardiac, renal and liver diseases,
between the normal and abnormal ABG groups. The pa-
tients in the abnormal ABG group had a higher ratio of
pulmonary comorbidity (chronic obstructive pulmonary
disease [COPD]/IP) compared with those in the normal
ABG group.
There were 16 major and 117 minor complications in the
remaining 133 patients. The 16 major complications com-
prised: postoperative bleeding that required re-exploration/
interventional radiology in two patients; cerebral infarction
in one; respiratory failure/pneumonia that required mech-
anical ventilation in nine (including one with acute exacer-
bation of interstitial pneumonia previously described); and
other organ failure in four. Minor complications occurred
in 117 patients. Prolonged air leakage occurred in 50
(12.1 %) and supraventricular arrhythmia in 27 (5.8 %).
There were no significant differences in postoperative com-
plications between the normal and abnormal ABG groups.
Long-term postoperative outcome
Although ten patients (2.4 %) were lost during follow-up,
no patient was lost for ≥2 years. The overall mean dur-
ation of follow-up was 5.6 years (range 0.1–16.2 years)
and 2343 patient-years were detected. There were 65
deaths from lung cancer, 80 from other diseases, including
23 related to other cancers, and 269 patients were still
alive, including 16 with lung cancer recurrence. In the
normal ABG group (n = 269), there were 35 deaths from
lung cancer (13 %), 47 from other diseases (17 %) and 187
patients were still alive (70 %), whereas in the abnormal
ABG group (n = 145), there were 30 deaths from cancer
(21 %), 33 from other diseases (23 %) and 82 patients were
still alive (56 %). As shown in Fig. 1, the 3-, 5- and 10-
year survival rates in the normal and abnormal ABG
groups were 87, 77 and 56 %, and 78, 63 and 42 %, re-
spectively (p = 0.006). As shown in Fig. 2, there were no
significant differences in survival between those with
normal versus abnormal pH (p = 0.067), and normal
versus low PaO2 (<80 Torr) (p = 0.251). The survival
rates in the high (p = 0.049) and low (p <0.001) PaCO2
groups were significantly lower than those in the nor-
mal PaCO2 group.
Although there were no significant differences between
the two groups for cause of death (p = 0.554), the all-
cancer-related (including secondary or any prior tumors)
and non-cancer-related survival rates in the abnormal
ABG group were significantly poor compared with those
in the normal group (p = 0.038 and 0.041, respectively) as
shown in Fig. 3.
Multivariate analysis of ABG and clinical functions
According to the log-rank test, gender, age, PS (0–1 vs 2),
ABG, postoperative predicted PFTs, histology, degree of
tumor differentiation, pathological stage, postoperative
complications and some preoperative comorbidity (cardiac,
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cerebral and liver disease and any prior tumor history)
were significantly associated with survival, as shown in
Table 3. According to multivariate analysis applying
the above significant variables, gender, age, PS, hist-
ology (non-adenocarcinoma), differentiation, patho-
logical stage, any prior tumor and ABG (risk ratio,
1.61; p = 0.006) were independent predictors of overall
survival. When multivariate analysis was performed
using ABG variables, both high PaCO2 (risk ratio, 1.84;
p = 0.016) and low PaCO2 (risk ratio, 1.99; p = 0.043)
were identified as independent factors.
Discussion
The key finding of this study is that preoperative ABG is a
predictor of long-term prognosis in stage I NSCLC, inde-
pendent of other important determinants such as age,
gender, PS and pathological stage. H–J classification, pre-
dicted postoperative PFTs, and cardiac/cerebral disease,
which are considered important physiological factors,
were not independent prognostic factors according to
multivariate analysis.
To select a subgroup of patients with stage I disease that
might benefit from adjuvant therapy, many investigators
Table 1 Clinicopathological characteristics according to normal or abnormal ABGs
Group Patients Normal ABG Abnormal ABG p value
(n = 269) (n = 145)
Age (years) <70 233 164 69 0.009
≥70 181 105 76
Gender Male 250 159 91 0.469
Female 164 110 54
BMI (Kg/m2) 22.2 ± 3.2 22.0 ± 3.4 0.539
Smoking History Yes 261 165 96 0.326
No 153 104 49
PS 0-1 384 250 134 0.844
2 30 19 11
H–J classification 1-2 401 261 140 0.792
3 13 8 5
Predicted post PFTsa) ≥40 383 253 130 0.105
<40 31 16 15
Histology Ad 302 203 99 0.326
Sq 99 57 42
Others 13 9 4
Differentiation Well 133 87 46 0.898
Mod/poor 281 182 99
p-stage IA 233 160 73 0.068
IB 181 109 72
Location Rt. upper 133 89 44 0.815
Rt. middle 28 17 11
Rt. lower 86 59 27
Lt. upper 92 57 35
Lt. lower 74 46 28
Surgical procedure Lobectomy 405 265 140 0.197
Bilobectomy 9 4 5
Blood loss (g) 125 ± 141 137 ± 143 0.234
Operative time (min) 192 ± 65 203 ± 67 0.483
Adjuvant therapy Yes 53 29 24 0.099
No 361 240 121
ad adenocarcinoma; BMI body mass index; p-stage pathological stage; sq squamous carcinoma
aPredicted postoperative values of FEV1.0 or DLCO <40 % are defined as high-risk results of pulmonary function tests
Mizuguchi et al. BMC Surgery  (2016) 16:3 Page 4 of 8
have attempted to identify pathological prognostic factors.
These attempts have included analysis of histological
subtype, size of primary tumor, degree of tumor differ-
entiation, tumor markers, and lymphatic or vascular in-
vasion [20, 21]. Recent studies have reported that the
following molecular markers are associated with poor
prognosis or recurrence in stage I NSCLC: cell cycle
regulation/apoptosis, angiogenesis, growth regulation,
cellular adhesion, cell cycle regulation, and basement
membrane invasion [20, 22]. As for physiological factors,
age, gender, PS, weight loss, depressed mood, quality of
life, smoking [20], Charlson Comorbidity Index score [23],
FEV1.0/DLCO [8–10] have been reported as long-term
prognostic factors in patients undergoing pulmonary re-
section. The Charlson Comorbidity Index allots weighted
scores based on the relative mortality risk to 19 factors
that were found to significantly influence survival in the
study subjects [23, 24]. Although these 19 factors include
Abnormal ABG
Normal ABG
0 2 4 6 8 10 12
Patients at risk
244 178 106 63 34 18
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Fig. 1 Survival rates of patients with resected stage 1 NSCLC according
to preoperative ABG values. The survival of patients with abnormal ABG
is significantly shorter than that in patients with normal ABG.
Table 2 Preoperative comorbidity and postoperative complications according to normal or abnormal ABGs
Group Patients Normal ABG Abnormal ABG p value
(n = 269) (n = 145)
Preoperative comorbidities
Hypertension 105 63 42 0.216
Diabetes mellitus 61 37 24 0.444
Cerebral disease 36 20 16 0.215
Cardiovascular disease 53 32 21 0.459
COPD/IP 64 32 32 0.006
Moderate-to-sever renal diseasea) 84 55 29 0.914
Child-Pugh classification (B or C) 9 7 2 0.416
Any prior tumor 96 63 33 0.879
Postoperative complications
In-hospital mortality 1 0 1
Major complications 16 10 6 0.832
Re-exploration/IVR 2 1 1
Bronchopleural fistula 0 0 0
Cerebral infarction 1 1 0
Respiratory failure/pneumonia 9 5 4
Other organ failureb) 4 3 1
Minor complications 117 83 34 0.110
Continuous air leakage 50 34 16 0.633
Prolonged pleural effusion/chylothorax 31 21 10 0.737
Supraventricular arrhythmias 27 20 7 0.820
Atelectasis/obstructive symptoms 12 9 3 0.461
Wound/intrathoracic infection 11 7 4 0.925
Change in mental status 8 7 1 0.178
Paresis of recurrent laryngeal nerve 4 2 2 0.528
IVR, inverse ratio ventilation
aModerate-to-severe renal disease was defined as estimated glomerular filtration rate <60 mL/min/1.73 m2
bIncluding cardiac, renal and liver failure
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some such as heart failure, chronic pulmonary disease
and renal disease that could affect ABG, abnormal ABG
was not identified as a prognostic comorbidity factor in
that study.
The preoperative physiological assessment of a patient
being considered for surgical resection of lung cancer
must take into account the immediate perioperative risks
from comorbid cardiopulmonary disease, the long-term
risks of pulmonary disability, and the threat to survival
posed by inadequately treated lung cancer. As is evident
in recently published algorithms, selection based on
physiological variables of patients for major pulmonary
resection for NSCLC currently focuses on perioperative
outcomes [5]. Many authors have assessed physiological
prognostic factors in patients with NSCLC and focused
on PFTs, mainly preoperative or predicted postoperative
FEV1 and DLCO [7–10, 25–27]. Predicted postoperative
pulmonary function can be theoretically determined by
the amount of parenchymal resection. However, various
factors can also influence it, including site of resection
(upper or lower lobectomy), severity of pulmonary em-
physema/fibrosis, the surgical approach (open or video-
assisted thoracic surgery), and chemotherapy/radiation
therapy [26]. When multivariate analysis was performed
excluding ABG, predicted postoperative FEV1.0 and DLCO
(shown as predicted PFT) was an independent prognostic
marker (risk ratio, 1.79, 95 % CI, 1.01–3.02; p = 0.047) in
this study.
Abnormal ABG in patients with lung cancer undergoing
surgical resection is reportedly a comorbidity risk factor
(mainly respiratory disorder) [5, 11, 12]. However, this is
controversial because two series have reported that peri-
operative complications are not more numerous in pa-
tients with preoperative hypercapnia [25, 28]. In the
present study, we also found no significant difference in
postoperative complications, including respiratory failure,
between patients with preoperative CO2 in the normal
range and those with hypercapnia. When multivariate
analysis was performed using three ABG variables as for
physiological factors, both high and low PaCO2 were iden-
tified as independent factors and further, larger studies are
necessary to clarify these findings.
We did not routinely measure postoperative ABG in
patients without complications, therefore preoperative
or short-term changes in PaO2 or PaCO2 are unclear. In
a previous study, although small decreases in PaO2 were
detected after pneumonectomy, there were no significant
p = 0.038
p = 0.041
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Fig. 3 Overall survival based on cause of death in patients with stage
1 NSCLC according to preoperative ABG values: (a) all-cancer-related
and (b) non-cancer-related survival rates
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Fig. 2 Overall survival of patients with stage 1 NSCLC according to
preoperative ABG values: (a) pH, (b) PaO2 and (c) PaCO2
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decreases in PaO2 after minor resection (including lob-
ectomy) and no significant changes in PaCO2 after any
type of resection [27]. Low PaO2 (<80 Torr) was not a
comorbidity predictor of prognosis in patients with
early lung cancer undergoing pulmonary resection
(Fig. 2b, p = 0.251). This may be of interest regarding
home oxygen therapy.
We postulated that patients with abnormal ABGs
might have poor prognosis because of the increased
risk of non-cancer-specific death. It is important to
note that deaths from both cancer and other causes
were higher in the abnormal ABG group. It is possible
that abnormal ABGs might affect or be affected by
cancer biology, and further, larger studies are necessary
to clarify our findings and determine whether this
trend is significant.
Conclusion
In the present study, we found that preoperative ABGs,
not only hypercapnia but also hypocapnia are predic-
tors of long-term prognosis in stage I NSCLC. Surgical
strategies for patients with abnormal ABG values
should be planned considering not only immediate or
short-term risk, which relates to perioperative morbid-
ity and mortality, but also long-term survival risk.
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